Observational studyBMC infectious diseases2026
The effect of artificial intelligence-driven, computed tomography-based assessment of body composition parameters on 28-day mortality of patients with severe fever with thrombocytopenia syndrome: a retrospective cohort study.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundSevere fever with thrombocytopenia syndrome (SFTS) is a life-threatening infectious disease with high mortality. Although sarcopenia and myosteatosis are associated with adverse outcomes in multiple acute illnesses, their prognostic impact on SFTS remains unknown. This study aimed to evaluate the association between body composition parameters and 28-day mortality in SFTS patients, and to identify independent prognostic factors.
methodsIn this retrospective observational single-center study, 234 SFTS patients with complete clinical data and available computed tomography (CT) images were enrolled. Body composition indices, including skeletal muscle index (SMI), subcutaneous fat index (SFI), visceral fat index (VFI), and intermuscular fat index (IMFI), were measured at the 12th thoracic (T12) and 3rd lumbar (L3) vertebral levels using a validated artificial intelligence-driven CT segmentation model. Univariable logistic regression and least absolute shrinkage and selection operator (LASSO) regression were applied to screen candidate predictors of 28-day mortality, and multivariable logistic regression was used to identify independent risk factors and construct a prognostic model. Model performance was evaluated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Kaplan-Meier curves with the log-rank test were used to compare survival across different muscle phenotypes.
resultsThe overall 28-day mortality rate was 13.7% (32/234). T12-IMFI was identified as an independent risk factor for 28-day mortality (adjusted odds ratio [aOR] = 1.30, 95% confidence interval [CI] 1.04-1.63, P = 0.021). A prediction model comprising age, log₁₀-transformed viral load, procalcitonin (PCT), and T12-IMFI was constructed, which exhibited satisfactory discrimination performance with an area under the ROC curve (AUC) of 0.877 (95% CI 0.805-0.950) and good calibration (Hosmer-Lemeshow P = 0.278). DCA demonstrated that the model provided superior net benefit across the clinically relevant threshold range of 0.05 to 0.68. The addition of T12-IMFI significantly improved individual risk stratification compared with the clinical-only model (net reclassification improvement [NRI] = 0.470, 95% CI 0.078- 0.862, P = 0.019). Patients with myosteatosis alone showed the highest 28-day mortality rate (26.1%), and significant differences in survival were observed among the four muscle phenotypes (log-rank P = 0.012).
conclusionsCT-defined myosteatosis, rather than sarcopenia, is independently associated with 28-day mortality in SFTS patients. T12-IMFI is a valuable prognostic biomarker, and the model incorporating T12-IMFI provides a practical tool for early risk stratification in SFTS patients at admission. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.